Filters

Ethan S Burstein, Christine Sandiego, Brian Raether, Xiaoshu Feng, Bryan Dirks, Mona Darwish, Peter Zhang, David S Russell, Eugenii A Rabiner, Sanjeev Pathak

Clinical pharmacology in drug development 2026;15(9):e70096

Full Text

Abstract

Safety and tolerability review of lorcaserin in clinical trials.

F L Greenway, W Shanahan, R Fain, T Ma, D Rubino

Clinical obesity 2017;6(5):285-95

Full Text

Abstract

Effects of lorcaserin on fat and lean mass loss in obese and overweight patients without and with type 2 diabetes mellitus: the BLOSSOM and BLOOM-DM studies.

C Apovian, K Palmer, R Fain, C Perdomo, D Rubino

Diabetes, obesity & metabolism 2017;18(9):945-8

Full Text

Abstract

A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.

Steven R Smith, Neil J Weissman, Meredith C Fidler, Matilde Sanchez, Brian Raether, William R Shanahan, Christen M Anderson

The Journal of clinical endocrinology and metabolism 2011;96(10):3067-77

Full Text

Abstract

Psychedelics as Medicines: An Emerging New Paradigm.

C D Nichols, M W Johnson, D E Nichols

Clinical pharmacology and therapeutics 2017;101(2):209-219

Full Text

Abstract

Multicenter, placebo-controlled trial of lorcaserin for weight management.

Steven R Smith, Neil J Weissman, Christen M Anderson, Matilde Sanchez, Emil Chuang, Scott Stubbe, Harold Bays, William R Shanahan

The New England journal of medicine 2010;363(3):245-56

Free Full Text

Abstract

Results: 1 – 15 / 17

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Serotonin 5-HT2 Receptor Agonists""[mesh_terms]

Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile.

5-hydroxytryptamine medications for the treatment of obesity.

Therapeutic use of serotoninergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms.

Experimental evaluation of the generalized vibrational theory of G protein-coupled receptor activation.

Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity.

Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women.

The safety and efficacy of lorcaserin in the management of obesity.

Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2.

Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis.

An Open-Label Study Investigating the 5-HT2A Receptor Occupancy of Remlifanserin (ACP-204) With the PET Radioligand [18F]Altanserin in Healthy Male Participants.

Safety and tolerability review of lorcaserin in clinical trials.

Effects of lorcaserin on fat and lean mass loss in obese and overweight patients without and with type 2 diabetes mellitus: the BLOSSOM and BLOOM-DM studies.

A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.

Psychedelics as Medicines: An Emerging New Paradigm.

Multicenter, placebo-controlled trial of lorcaserin for weight management.

Results for
""Serotonin 5-HT2 Receptor Agonists""[mesh_terms]

An Open-Label Study Investigating the 5-HT_2A Receptor Occupancy of Remlifanserin (ACP-204) With the PET Radioligand [¹⁸F]Altanserin in Healthy Male Participants.